Amy C. Peterson, M.D., serves as the Executive Vice President of Product Development & Medical Affairs, and Chief Medical Officer at Exelixis, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of new medicines to treat cancer. Dr. Peterson brings a wealth of experience to her role, having spent over two decades in the biopharmaceutical industry. She joined Exelixis in 2016 and has been instrumental in guiding the company's clinical development strategy and medical affairs initiatives. Prior to joining Exelixis, Dr. Peterson held several leadership positions at other notable biopharmaceutical companies. She was the Senior Vice President of Clinical Development at Medivation, Inc., where she played a key role in the development and approval of enzalutamide, a groundbreaking treatment for prostate cancer. Before Medivation, she served as Vice President of Clinical Development at Genentech, Inc., where she contributed to the development of several successful oncology drugs. Dr. Peterson's extensive experience in clinical development and her deep understanding of oncology have been crucial to Exelixis' success in advancing its pipeline of innovative cancer therapies. As Chief Medical Officer at Exelixis, Dr. Peterson oversees the company's clinical development programs, ensuring that they are designed and executed to the highest standards. She also leads the medical affairs team, which is responsible for communicating the scientific and clinical value of Exelixis' products to healthcare professionals and patients. Under her leadership, Exelixis has made significant progress in expanding the indications for its flagship product, cabozantinib, and advancing its pipeline of novel targeted therapies. Dr. Peterson's strategic vision and dedication to improving patient outcomes have made her an invaluable asset to Exelixis and the broader oncology community.